Tristel plc
("Tristel" or the "Company")
Pre-close trading update and notice of results
Tristel plc (AIM: TSTL), the manufacturer of infection prevention, contamination control and hygiene products, provides a trading update following the end of its financial year on 30 June 2014. Tristel addresses three distinct markets: Human Healthcare, Animal Healthcare and Contamination Control, with three distinctively branded product ranges: Tristel, Anistel and Crystel.
The Company enjoyed a strong second half performance which has led to a fifth profit upgrade this financial year. The preliminary results for the year ended 30 June 2014 will be released on 13 October 2014 and will show revenues and pre-tax profit ahead of expectations that were last updated in June.
Trading highlights
· H2 revenues of £7.04m up by 9.3% on H1 (£6.44m)
· Full year revenues of £13.48m up 27.7% on previous year (2013: £10.56m)
· Full year pre-tax profit of £1.8m before share based payments (2013: adjusted* pre-tax profit of £0.48m)
· Net cash of £2.59m at 30 June (2013: £0.49m)
*Adjusted for non-recurring items of £2.2m
Paul Swinney, Chief Executive, comments "The Company ended its financial year in good shape. The improved performance achieved over the past twelve months relates to all areas of the Group and is expected to continue into the new financial year and beyond."
For further information please contact:
Tristel plc |
|
Paul Swinney, Chief Executive Officer |
Tel: 01638 721 500 |
Liz Dixon, Finance Director |
|
|
|
Walbrook PR Ltd |
Tel: 020 7933 8780 or tristel@walbrookpr.com |
Paul McManus |
Mob: 07980 541 893 |
Lianne Cawthorne |
Mob: 07854 391 303 |
|
|
finnCap |
Tel: 020 7600 1658 |
Geoff Nash (Corporate Finance) |
|
Charlotte Stranner (Corporate Finance) |
|
Stephen Norcross (Corporate Broking) |
|